Surgical Valve Replacement Might Soon Be History

Reference: Pierre Deharo et al. J Am Coll Cardiol 2020;76:489–99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Patients with dysfunctional biological prosthetic valves have better outcomes with TAVR vs. surgical reintervention, beyond surgical risk. This study outcomes might even call into question the age cutoff to consider a mechanical vs. a biological prosthesis at first surgery.

reoperación valvular

This analysis recently published in JACC looked at the outcomes of both possible strategies to treat a dysfunctional biological prosthesis, surgical reintervention and valve-in-valve.

It included 4327 patients in France with dysfunctional biological prosthesis between 2010 and 2019, which were compared using propensity score.

After matching, 717 with identical clinical and risk profile were left in each arm.

At 30 days, valve-in-valve was associated to lower end point rate, a combination of all cause death, stroke, MI and life-threatening major bleeding (OR: 0.62; CI 95%: 0.44 to 0.88; p=0.03). Up to this point, there were no big surprises, since a less invasive procedure will always have an acute benefit over a more aggressive one.


Read also: High Mortality Rates for Redo Surgery After TAVR.


At long term follow-up (mean 516 days) the combined end point (plus repeat hospitalization for cardiac failure) resulted similar between both arms (OR: 1.18; CI 95%: 0.99 s 1.41; p=0.26).

Repeat hospitalization for cardiac failure and pacemaker implantation were more frequent in the TAVR group.

Despite the latter, there was a clear interaction between all cause and cardiovascular mortality with valve-in-valve.


Read also: Is V-in-V the Treatment of Choice in Cases of Failed Biological Prosthesis?


These results are in line with the summary from the European Heart Journal we published on August 4, 2020.

Conclusion

Valve in valve is associated with better outcomes at short term and similar outcomes at long term vs. surgical reintervention in patients with dysfunctional biological prothesis in aortic position.  

Original Title: Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement.

Reference: Pierre Deharo et al. J Am Coll Cardiol 2020;76:489–99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...